Total | Avastin | Herceptin | Lucentis | Nutropin | Pulmozyme | Raptiva | Rituxan | Tarceva | Thrombolytics | Xolair | Other

Other U.S. Sales $ in millions

	Q1	Q2	Q3	Q4	Year Total
1996	$ 0.8	$ 1.1	$ 1.5	$ 1.0	$ 4.5
1995	$ 1.0	$ 0.9	$ 1.0	$ 0.8	$ 3.6
1994	$ 1.6	$ 0.9	$ 1.9	$ 2.0	$ 6.4
1993	$ 1.3	$ 1.3	$ 0.8	$ 0.8	$ 4.3
1992	$ 0.6	$ 0.8	$ 0.8	$ 0.7	$ 2.9
1991	$ 0.1	$ 0.3	$ 0.5	$ 0.8	$ 1.7

Other Sales to Collaborators $ in millions

	Q1	Q2	Q3	Q4	Year Total
2005	$ 19.7	$ 8.7	$ 2.2	$ 0.9	$ 31.5
2004	-	-	-	$ 10.6	$ 10.6
2003	-	-	$ 1.7	$ 4.8	$ 6.5
2002	-	-	-	-	-
2001	$ 0.9	$ 1.6	$ 2.9	$ 1.9	$ 7.3
2000	$ 0.0	$ 0.9	$ 1.9	$ 0.9	$ 3.7
1999	$ 0.7	$ 0.7	$ 0.4	$ 0.9	$ 2.7
1998	$ 0.9	$ 1.0	$ 1.0	$ 1.0	$ 3.9
1997	$ 0.8	$ 0.8	$ 0.8	$ 0.8	$ 3.2

Other Sales Total $ in millions

	Q1	Q2	Q3	Q4	Year Total
2005	$ 19.7	$ 8.7	$ 2.2	$ 0.9	$ 31.5
2004	-	-	-	$ 10.6	$ 10.6
2003	-	-	$ 1.7	$ 4.8	$ 6.5
2002	-	-	-	-	-
2001	$ 0.9	$ 1.6	$ 2.9	$ 1.9	$ 7.3
2000	$ 0.0	$ 0.9	$ 1.9	$ 0.9	$ 3.7
1999	$ 0.7	$ 0.7	$ 0.4	$ 0.9	$ 2.7
1998	$ 0.9	$ 1.0	$ 1.0	$ 1.0	$ 3.9
1997	$ 0.8	$ 0.8	$ 0.8	$ 0.8	$ 3.2
1996	$ 0.8	$ 1.1	$ 1.5	$ 1.0	$ 4.5
1995	$ 1.0	$ 0.9	$ 1.0	$ 0.8	$ 3.6
1994	$ 1.6	$ 0.9	$ 1.9	$ 2.0	$ 6.4
1993	$ 1.3	$ 1.3	$ 0.8	$ 0.8	$ 4.3
1992	$ 0.6	$ 0.8	$ 0.8	$ 0.7	$ 2.9
1991	$ 0.1	$ 0.3	$ 0.5	$ 0.8	$ 1.7

Other Sales are made up primarily of products that Genentech is not developing or commercializing but is manufacturing and selling directly to collaborator companies.

The totals may not appear to sum due to rounding.